Ipsen SA IPN
EURONEXT · France · Health Technology
€140.60-1.50 (-1.06%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Aggregated presentation by day and by market Weekly report on share repurchases from 21st September to 22nd September 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1121/09/2026FR001025915021 158146,4614XPARIPSEN549300M6SGDPB4Z94P1121/09/2026FR00102591507 870146,0726CEUXIPSEN549300M6SGDPB4Z94P1121/09/2026FR00
Ipsen (ENXTPA:IPN) has refreshed its governance, with the board appointing Mariette Finet as Director and member of the Board Portfolio Committee following Michèle Ollier’s resignation earlier in the summer. Ipsen’s share price has softened in the short term, with a 1-month share price return down 10.18% and a 7-day move lower by 4.30%. The stock is still up 28.42% year to date and has delivered a 35.14% total shareholder return over the past year, suggesting longer term momentum remains...
All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.